Merck has ceased its research operations across the UK and canceled plans for a £1.3 billion ($1.31 billion) research center in London, citing insufficient government support and policy challenges affecting the pharmaceutical sector. This significant retreat highlights ongoing tensions between drugmakers and the UK's life sciences funding approaches, particularly in response to pricing and access policies. Industry stakeholders view Merck’s decision as a critical indicator of the UK's challenges in retaining biopharma investment and fostering R&D growth.